Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageZymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat conditions, including cancer, inflammation, and autoimmune disease. We believe our asset and royalty aggregation strategy differentiates us from other biotechnology companies because it provides us with an opportunity to optimize future milestone and royalty cash flows and selectively invest in high-quality assets while retaining the flexibility to return capital to stockholders.
In the company’s own words · 10-K filed Mar 2, 2026 · SEC EDGAR
Business segments
Jun 2026 · $2.7MThe company’s own SEC segment disclosure.
- Royalty$1.6M59%
- Drug Supply For Ongoing Studies$791.0K29%
- Research Support Payments And Other Service$291.0K11%
- Drug Supply$45.0K2%
Zymeworks Inc. (ZYME) reported revenue of $2.4M in Q1 2026 (quarter ended Mar 31, 2026), down 91% from the same quarter a year earlier. That came with net loss of $44M. For the full year FY2025, revenue was $106M (+39% year on year) and net income −$81M. Its largest product in Jun 2026 was Royalty at $1.6M, 59% of the disclosed total, well ahead of Drug Supply For Ongoing Studies at 29%.
Raw charts
8 series · TTMAs reported to the SEC, without any scoring.